Business
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":" MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.\n\nInvestors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.\n\nAbout DiaMedica Therapeutics\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20221107005660/en/\n\nScott Kellen\nChief Financial Officer\nPhone: (763) 496-5118\[email protected]\n\nPaul Papi\nCorporate Communications\nPhone: 617-899-5941\[email protected]\n\nSource: DiaMedica Therapeutics Inc.","length":2696,"tagName":"div"}]